FDA Med Conference Study Raises Pharma Enforcement Risks

The U.S. Food and Drug Administration recently announced a new study on pharmaceutical companies' interactions with health care providers at exhibit booths during medical conferences.

According to the relevant Federal Register notice, the study is designed to "provide insights to inform the advisory comments that [the FDA's Office of Prescription Drug Promotion, or OPDP,] provides to pharmaceutical companies that voluntarily seek FDA review" of exhibit booth materials.